The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Uproleselan update: moving forward for R/R AML
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest data on uproleselan (GMI-1271), a novel E-selectin antagonist, in acute myeloid leukemia (AML). This includes the upcoming phase 3 registration trial in the relapsed/refractory setting (NCT03616470) and work showing that uproleselan can overcome the chemotherapy resistance that high E-selectin ligand expression contributes to. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
